SLP - Simulations Plus, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
20.24
-0.43 (-2.08%)
At close: 4:00PM EST

20.24 0.00 (0.00%)
After hours: 4:00PM EST

Stock chart is not supported by your current browser
Previous Close20.67
Open20.70
Bid16.69 x 900
Ask22.00 x 800
Day's Range20.16 - 20.73
52 Week Range14.25 - 23.95
Volume20,572
Avg. Volume53,978
Market Cap351.47M
Beta (3Y Monthly)-0.15
PE Ratio (TTM)41.22
EPS (TTM)0.49
Earnings DateNov 14, 2018
Forward Dividend & Yield0.24 (1.16%)
Ex-Dividend Date2018-10-31
1y Target Est20.50
Trade prices are not sourced from all markets
  • Does The Data Make Simulations Plus Inc (NASDAQ:SLP) An Attractive Investment?
    Simply Wall St.4 days ago

    Does The Data Make Simulations Plus Inc (NASDAQ:SLP) An Attractive Investment?

    As an investor, I look for investments which does not compromise one fundamental factor for another. By this I mean, I look at stocks holistically, from their financial health to Read More...

  • Business Wire7 days ago

    Simulations Plus to Report 4th Quarter and Fiscal Year 2018 Financial Results

    Conference Call to be on Wednesday, November 14, 2018, at 4:15 PM ET

  • Business Wire7 days ago

    DILIsym Services, an SLP Company, Launches Consortium for Drug-Related Kidney Injury

    DILIsym Services, Inc., a Simulations Plus company (SLP) and a leading provider of simulation and modeling software for pharmaceutical safety, today announced that it will initiate a quantitative systems toxicology (QST) consortium aimed at addressing the problem of drug-induced kidney injury, the third leading cause for clinical and late stage drug attrition in pharmaceutical development.

  • Simulations Plus (SLP) Q4 Earnings Preview: What's in the Cards?
    Zacks8 days ago

    Simulations Plus (SLP) Q4 Earnings Preview: What's in the Cards?

    Simulations Plus (SLP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wire22 days ago

    Simulations Plus Announces Quarterly Cash Dividend of $0.06 per Share

    Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that its board of directors has declared its next ongoing quarterly cash dividend of $0.06 per share of the Company’s common stock. The cash dividend will be distributed on Thursday, November 8, 2018, to shareholders of record as of Thursday, November 1, 2018. Walt Woltosz, chairman of the board of directors, said, “This dividend declaration is a continuation of the Board’s plan to distribute a cash dividend of $0.06 per share per quarter.

  • Simply Wall St.last month

    Is Simulations Plus Inc’s (NASDAQ:SLP) PE Ratio A Signal To Buy For Investors?

    This analysis is intended to introduce important early concepts to people who are starting to invest and want to start learning about core concepts of fundamental analysis on practical examples Read More...

  • How Simulations Plus Inc (NASDAQ:SLP) Delivered A Better ROE Than Its Industry
    Simply Wall St.2 months ago

    How Simulations Plus Inc (NASDAQ:SLP) Delivered A Better ROE Than Its Industry

    I am writing today to help inform people who are new to the stock market and want to learn about Return on Equity using a real-life example. Simulations Plus IncRead More...

  • Business Wire2 months ago

    Simulations Plus Receives New Grant Award from the FDA

    Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has received notice from the U.S. Food and Drug Administration (FDA) that it has been awarded a new funded cooperative agreement, for $250,000 per year for up to two years, to integrate drug product quality attributes into the mechanistic Transdermal Compartmental Absorption and Transit (TCAT™) model in GastroPlus™.

  • Business Wire2 months ago

    Simulations Plus Extends Funded Research Collaboration with the FDA

    Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has entered into a one-year funded extension to its previous cooperative agreement (grant 1U01FD005211) with the U.S. Food and Drug Administration (FDA) to further develop and validate the mechanistic Ocular Compartmental Absorption and Transit (OCAT™) model in GastroPlus™.

  • ACCESSWIRE4 months ago

    Ex-Dividend Schedule: Simulations Plus Has a Dividend Yield of 1.32%; Will Trade Ex-Dividend on July 25, 2018

    LONDON, UK / ACCESSWIRE / July 24, 2018 / Active-Investors has a free review on Simulations Plus, Inc. (NASDAQ: SLP) following the Company's announcement that it will begin trading ex-dividend on July 25, 2018. To capture the dividend payout, investors must purchase the stock a day prior to the ex-dividend date that is by latest at the end of the trading session on July 24, 2018. Active-Investors has initiated due-diligence on this dividend stock.

  • Business Wire4 months ago

    Simulations Plus Subsidiary DILIsym Awarded Grant for up to $1.7 Million For Model Development

    DILIsym Services, Inc., a Simulations Plus company (SLP) developing in silico modeling software, resources, and information for assisting the pharmaceutical industry to more efficiently develop safe and effective drug therapies, today announced it has been awarded a Fast-Track Small Business Innovation Research (SBIR) grant by the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK). The grant, coauthored by Dr. Brett Howell (Principal Investigator) and Dr. Bud Nelson, is entitled “Software for predicting a drug’s potential to cause acute kidney injury.” The total award for this Fast Track SBIR grant is up to $1.7 million over the next 18-24 months.

  • Business Wire4 months ago

    Simulations Plus Enters Funded Research Collaboration with Large European Consortium

    Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has entered into a one-year funded research collaboration with a large European consortium to further develop and validate the mechanistic Transdermal Compartmental Absorption and Transit (TCAT™) model in GastroPlus™. Dr. Viera Lukacova, director of simulation sciences, said: “We are very pleased to have the opportunity to work with the diverse membership of this large European consortium to enhance the GastroPlus TCAT model in support of alternative approaches to animal testing. The model is already being utilized heavily within pharmaceutical companies to support transdermal product development activities.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of SLP earnings conference call or presentation 10-Jul-18 8:15pm GMT

    Q3 2018 Simulations Plus Inc Earnings Call

  • Simulations Plus, Inc. (SLP) Q3 2018 Earnings Conference Call Transcript
    Motley Fool4 months ago

    Simulations Plus, Inc. (SLP) Q3 2018 Earnings Conference Call Transcript

    SLP earnings call for the period ending May 31, 2018.

  • Associated Press4 months ago

    Simulations Plus: Fiscal 3Q Earnings Snapshot

    On a per-share basis, the Lancaster, California-based company said it had net income of 13 cents. The maker of software used in pharmaceutical research posted revenue of $8.6 million in the period. Simulations ...

  • Business Wire4 months ago

    Simulations Plus Reports Third Quarter FY2018 Financial Results

    Record quarter as revenues grow 26.7%, 9MoFY18 net income up 63.8%

  • ACCESSWIRE4 months ago

    Simulations Plus, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / July 10, 2018 / Simulations Plus, Inc. (NASDAQ: SLP ) will be discussing their earnings results in their Q3 Earnings Call to be held on July 10, 2018 at 4:15 PM Eastern Time. ...

  • Business Wire4 months ago

    Company Profile for Simulations Plus, Inc.

    Simulations Plus, Inc., is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions and quantitative systems pharmacology/toxicology models for drug-induced liver injury and nonalcoholic fatty liver disease.

  • Business Wire4 months ago

    Simulations Plus to Report Third Quarter 2018 Financial Results

    Simulations Plus, Inc. (SLP), announced today that it will report its third quarter financial results for fiscal year 2018, the period ended May 31, 2018, after the close of the financial markets on Tuesday, July 10, 2018. The Company invites all interested persons to attend its conference call at 4:15 p.m. Eastern Time on July 10, 2018. Simulations Plus, Inc., is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions.

  • Business Wire5 months ago

    Simulations Plus Releases ADMET Predictor™ Version 9

    Simulations Plus, Inc. , the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has released version 9 of its flagship artificial intelligence modeling program, ADMET Predictor™.

  • Business Wire5 months ago

    Simulations Plus Names Shawn O’Connor as CEO

    Simulations Plus, Inc. (SLP), the premier provider of simulation and modeling software and consulting services for all stages of pharmaceutical discovery and development, today announced that Shawn M. O’Connor will become its chief executive officer effective June 26, 2018. Mr. O’Connor brings more than three decades of executive experience from multiple industries with companies ranging from start-ups to publicly traded companies and a proven track record for strategy definition, building strong organizations, optimizing revenue, profitability, and cash flow, and creating value for investors.

  • Business Wire5 months ago

    Simulations Plus to Present at the 8th Annual LD Micro Invitational Investor Conference on June 5, 2018

    Simulations Plus, Inc. , the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, and chemical industries, today announced that it will participate in the 8th Annual LD Micro Invitational Investor Conference to be held at the Luxe Sunset Boulevard Hotel in Los Angeles.

  • Business Wire6 months ago

    Simulations Plus Releases GastroPlus™ Version 9.6

    Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, and chemicals industries, today announced that it has released version 9.6 of its flagship PBPK modeling program, GastroPlus™. With the ever-increasing emphasis on PBPK modeling from regulatory agencies globally, the client base for GastroPlus continues to expand.

  • Is Simulations Plus Inc’s (NASDAQ:SLP) ROE Of 28.61% Sustainable?
    Simply Wall St.6 months ago

    Is Simulations Plus Inc’s (NASDAQ:SLP) ROE Of 28.61% Sustainable?

    Simulations Plus Inc (NASDAQ:SLP) outperformed the Health Care Technology industry on the basis of its ROE – producing a higher 28.61% relative to the peer average of 15.28% over theRead More...

  • Business Wire6 months ago

    Simulations Plus to Present at the Needham Emerging Technology Conference on May 16, 2018

    Simulations Plus, Inc. (SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development from the earliest discovery through all phases of clinical trials, today announced that chairman and chief executive officer, Walt Woltosz, will present at the Needham Emerging Technology Conference on Wednesday, May 16, 2018, at 3:00 p.m. ET and will conduct one-on-one meetings throughout the day. Simulations Plus, Inc. is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical and biotechnology agents.